Biophytis SaEURONEXT: ALBPS

Biophytis S A obtains EMA authorization to launch its Phase 2 clinical trial in obesity

· Issued by Biophytis Sa

03 Sep 2025 07:00 CEST

Subscribe
Issuer

BIOPHYTIS

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1355837_Approval_EMA_Biophytis_Phase_2_OBA_Sept_2025_VENG.pdf

Source

Biophytis

Provider

Les Echos

Company Name

BIOPHYTIS

ISIN

FR001400OLP5

Symbol

ALBPS

Market

Euronext Growth